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ABSTRACT 
   
 Seasonal reproduction is highly correlated with circulating concentrations of 
luteinizing hormone (LH) in mares and low peripheral concentrations of LH serve as the 
primary basis for ovarian quiescence during the non-breeding season. Four experiments 
were conducted to investigate the effects and underlying relationships of 1-
adamantanecarbonyl-RF-NH2 (RF9) and estradiol in the regulation of LH secretion. 
During the luteal phase of the estrous cycle (Experiment 1), mares were treated with two 
bolus intravenous injections of RF9 (0.2 and 0.4 mg/kg, respectively) within a 1-h 
interval to determine effects on secretion of gonadotropin-releasing hormone (GnRH), 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Dose-dependent 
increases (P < 0.05) in both FSH and LH concentrations in response to RF9 were 
observed.  Due to an inability to validate the GnRH radioimmunoassay, changes in 
secretion of GnRH could not be determined.  In Experiment 2, the effect of estradiol-17β 
(estradiol) pretreatment on responsiveness to RF9 was examined in winter anovulatory 
mares. Mares received a single intramuscular injection of corn oil of 5 mg estradiol in 
corn oil followed by a bolus injection of RF9 18 h later. Estradiol pretreatment increased 
(P < 0.05) peak concentrations of LH in response to RF9. The half-life of RF9 in the 
circulation of the mare following peripheral administration was determined in 
Experiment 3 using liquid chromatography and mass spectrometry. Intravenously-
injected RF9 was rapidly removed from the mare’s circulatory system; exhibiting a half-
life of approximately 40 min. Finally, the role of estradiol and its interaction with GnRH 
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in regulating secretion of LH in anovulatory mares during increasing photoperiod was 
examined.  In February, mares were assigned to 1 of 4 groups and served as controls 
(corn oil injections) or received 1 of 3 treatments: daily i.m. injections of estradiol in 
corn oil for 14 d, continuous subcutaneous treatment with native GnRH for 14 d at a rate 
of 100 µg/h, or the estradiol and GnRH treatments in combination. Estradiol alone had 
no effect on secretion of LH but markedly enhanced (P < 0.0002) responsiveness to 
GnRH.  Due to its short half-life, RF9 may not be useful therapeutically; however, 
estradiol enhances responsiveness to GnRH and may be useful in treatments designed to 
accelerate vernal transition. 
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NOMENCLATURE 
 
BCS Body condition score  
CL Corpus luteum 
FSH Follicle stimulating hormone 
GnIH Gonadotropin-inhibitory hormone 
GnRH Gonadotropin-releasing hormone 
GPR147 G-protein coupled receptor 147 
ICS Intercavernous sinus 
LH Luteinizing hormone 
LC/MS  Liquid Chromatograph and Mass Spectroscopy 
RF9 Adamantanecarbonyl-Arg-Phe-NH2 
RIA Radioimmunoassay 
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CHAPTER I 
INTRODUCTION 
  
 Mares are long-day breeders, with seasonal reproductive cycles occurring as a 
consequence of an endogenous circannual rhythm controlled primarily by photoperiod 
[1]. In the Northern Hemisphere, the natural breeding season of the horse falls between 
April and October, with approximately 85% of standard light-horse mares becoming 
anovulatory around the time of the autumnal equinox [1].  However, the operational 
breeding season is currently initiated well in advance of the natural breeding season in 
most commercial horse breeding operations in North America, particularly those 
representing the major breed organizations such as Thoroughbred, American Quarter 
Horse, and Standardbred etc [2]. This has occurred because January 1 has been adopted 
as the official birthdate of foals in the majority of these breed registries. The basis for the 
advanced operational breeding season is that the earlier a foal is born in the calendar 
year, the more time it has to grow and mature compared to a foal born later. Results of 
regional Thoroughbred yearling race horse sales suggest that there is a significant 
economic gain by assuring that foal dates are as close to January 1 as possible. Foals 
born in January and February were worth an estimated 30% more and March to April 
foals 18% more than foals born after April [3]. 
  A common method used by most commercial breeders to initiate ovarian 
cyclicity in seasonally anovulatory mares is to  supplement artificial lighting, 
maintaining a minimum of 14.5 to 16 h of light per day, beginning 60 to 90 d prior to the 
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intended breeding season [1,4]. This method has proven to be an effective way of 
initiating the onset of ovarian cyclicity in the mare and to lengthen the operational 
breeding season [1].  However,  individual responses can be quite variable and the costs 
of time, labor and infrastructure needed to implement a lighting program are significant 
[5]. Thus, there are economic incentives for improving our understanding of 
fundamental neuroendocrine mechanisms controlling reproductive seasonality in the 
mare and for developing novel pharmacological methodologies to consistently time the 
first and subsequent ovulations during the operational breeding season. 
Several neuroendocrine signaling pathways involved in regulating the transition 
from non-breeding to breeding seasons in the mare have been described. These include 
changes in secretion of melatonin [6], endogenous opioidergic and dopaminergic tone 
[7], secretion of gonadotropin-releasing hormone (GnRH), and stimulatory effects of 
ovarian and placental steroid hormones on gonadotropin secretion post-foaling (foal 
heat) and during vernal transition. Most recently, the putative role of a novel peptide first 
discovered in seasonally-breeding birds, gonadotropin inhibitory hormone (GnIH) has 
been examined in the mare for the first time by our group [8].  In addition, we were the 
first to evaluate a putative antagonist, 1-adamantanecabonyl-RF-NH2 (RF9), of the 
receptor signaling pathways for GnIH in the mare [8]. Studies suggested that RF9 may 
be a prospective pharmaceutical means of manipulating seasonal reproduction based on 
its ability to initiate a robust increase in circulating luteinizing hormone (LH) [8,9]. 
However, further research is needed to investigate the biological effects of RF9, its 
potential value as a pharmaceutical agent, and roles of ovarian steroid hormones, 
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particularly estradiol, in modulating RF9’s hypothalamic effects.  In fact, the role of 
estradiol in modulating traditionally-accepted aspects of hypothalamic-
adenohypophyseal function in the mare has also remained controversial, especially 
during vernal transition. In some studies, estradiol has been shown to be stimulatory and 
to interact positively with photoperiod to stimulate secretion of LH during this period 
[10-12].  However, other studies failed to support those findings [12].  
The objectives of research reported in this thesis were to determine 1) whether 
RF9 stimulates the secretion of GnRH, as measured in the intercavernous sinus of the 
mare, in concert with secretion of follicle stimulating hormone (FSH) and LH, 2) the 
half-life of RF9 in the circulation of the mare following peripheral administration, 3) 
whether estradiol modulates hypothalamic responsiveness to RF9, and 4) the role of 
estradiol and its interaction with GnRH in regulating secretion of LH during increasing 
daylight.   
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Overview of Annual Reproductive Cycle 
Characteristic changes associated with reproductive seasonality in the mare are 
indicated by the hormonal patterns throughout the year, and are accentuated by marked 
changes in the mean concentration of LH present in the circulation.  For mares during 
the natural breeding season in the Northern Hemisphere, concentrations of LH begin to 
increase from  baseline values approximately one month prior to the first annual 
ovulation (March-May) [13]. During this period, concentrations of circulating LH 
continue to increase and ovarian follicular dynamics begin to change.  While follicular 
waves are present throughout the transition period leading up to the first ovulation, the 
number of  follicles >20mm in diameter within each wave begins to increase during 
vernal transition [13].  Prior to ovulation, selection of a dominant follicle occurs at 
deviation and both circulating concentrations of LH and size of the dominant follicle 
increase rapidly until ovulation, while smaller follicles become atretic [13,14].  
Maximum peak concentrations of LH in the mare occur approximately 1 to 2 d after 
ovulation [15]. With respect to the overall cycle, mean circulating concentrations of LH 
continue to increase until approximately the mid-breeding season (June-July). The 
majority of mares enter into a winter anovulatory period following the autumnal 
equinox, with circulating concentrations of LH reaching their nadir by the middle of the 
non-breeding season (Dec.-Jan) [1,13,16-18].  
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The annual reproductive cycle of the mare, or circannual rhythm, is dictated 
primarily by changes in photoperiod [1,5,19].  The pineal gland, acting as a transducer, 
translates the photoperiodic signal by altering its secretion of melatonin [19-21]. 
Grubaugh, et al. [6] was able to demonstrate that pinealectomized mares become non-
responsive to photostimulation, creating a disconnect in the long term timing of seasonal 
regulation.  While melatonin’s mechanism of action has yet to be completely elucidated, 
it has been shown to alter hypothalamic release of GnRH and thus the release of 
gonadotropins, LH and FSH and the subsequent regulation of follicular development 
[13,20].   
 
2.2 Melatonin  
In short day breeders, such as sheep and goats, supplementation with melatonin 
has been shown to have some positive effects on reproductive performance, but has 
limited success in advancing the onset of  estrus in seasonally anovulatory ewes [20,22-
24].  As a means to hasten the onset of estrous cycles in the seasonally anovulatory 
mare, treatment with melatonin would not appear to be justified as it has been shown to 
slow the increase in LH during spring transition, ultimately extending the interval to first 
ovulation [25].  It should be noted, however, that continuous melatonin treatment after 
the summer solstice has been shown to advance the ovulatory season the following year, 
with the early onset being explained by short day refractoriness brought on by the early 
increase in melatonin [25,26].  Nonetheless, melatonin treatment seems to have little 
practical application in the advancement of estrus during the non-breeding season. 
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2.3 Opioids 
Endogenous opioid inhibition of the hypothalamic-pituitary axis has also been 
noted in equine, as it is thought to play a role in seasonal regulation and GnRH inhibition 
during the luteal phase. Alexander [27] reported an increase in both amplitude and 
frequency of GnRH, FSH, and LH pulses during the breeding season from pituitary 
venous samples following a bolus i.v. injection of naloxone (0.2 mg/kg BW), an opioid 
antagonist, prior to ovulation.  When evaluating the response of anovulatory mares to 
naloxone, results varied, with some groups exhibiting an immediate increase in secretion 
of LH following treatment [28,29], while another group showed a dose dependent 
increase in FSH only [30]. Sharp, et al. [31] was unable to suppress the opioid inhibition 
of LH with high doses of naloxone (2 mg/kg), possibly a result of a bell-shaped response 
curve noted in later work by Irvine [32]. Davison and co-workers suggested that mares 
that continue to exhibit ovulatory cycles during the non-breeding season may have 
reduced opioidergic tone, as they exhibited an increase in LH following naloxone 
treatment, similar to that of mares during the breeding season [30]. 
 
2.4 Catecholamines 
Similar regulation of hypothalamic-pituitary function has been reported in 
response to endogenous dopamine. Melrose, et al. [33] evaluated concentrations of 
catecholamines in the cerebrospinal fluid (CSF) of horses by age and reproductive status 
and found that concentrations of dopamine were significantly greater during the 
anovulatory season in comparison to the ovulatory season in the mare. This information 
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has led to numerous investigations using dopamine antagonists to evaluate dopamine’s 
participation in seasonal regulation of reproduction in the mare. Results were variable, 
with some studies showing an increase in follicular activity and a decrease in time to 
onset of ovarian cyclicity in the spring [34-37], and others showing no effect [38-40]. 
Similar variability was observed when evaluating gonadotropin response to dopamine 
antagonists, with no acute increases in LH reported in some studies [7,41] and long-term 
treatment producing an increase in mean circulating LH and FSH [35,37]. Even with this 
variable response in cyclicity and gonadotropic response, there does seem to be an 
increase in prolactin in a number of studies [34,35,40]. Recombinant porcine prolactin 
has been shown to shorten the days to first ovulation and induce shedding in the 
anestrous mare, suggesting that that dopamine antagonists may have some stimulatory 
effect indirectly through prolactin [42]. 
 
2.5 Gonadotropin-Releasing Hormone 
The central dogma of gonadotropic hormone regulation involves the anterior 
pituitary release of LH and FSH in response to hypothalamic secretion of GnRH. This 
suggests that the seasonal regulation of reproduction occurs through hypothalamic 
release of GnRH. Silvia, et al. [43] observed no differences in hypothalamic content of 
GnRH or the concentration of GnRH receptors in the anterior pituitary of mares during 
winter anovulation, the spring transitional period and breeding season. However, 
concentrations of pituitary LH increased markedly between the non-breeding and 
breeding seasons. However, Hart [18] found a correlation between hypothalamic content 
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of GnRH between seasons with content being  lowest during non-breeding season but 
not anterior pituitary receptors for GnRH during the breeding season, non-breeding 
season, vernal transition and late breeding season. Similarly, Sharp [44] observed an 
increase in GnRH secretion rate in cerebrospinal fluid using a push-pull perfusion 
technique from the non-breeding season to the breeding season. Due to the unique 
cranial vasculature of  the horse, early work by Irvine, Hunn [45] and Irvine, Alexander 
[46] made it possible to measure GnRH and gonadotropins directly from pituitary 
venous effluent. The technique allowed for the cannulation of the intercavernous sinus 
(ICS) through the superficial facial vein.  In the mare, episodic secretion patterns of LH 
are not measurable in the peripheral circulation except during the mid-luteal phase. 
Moreover, similar to other mammalian species, secretion of GnRH typically must be 
measured either in hypophyseal portal blood or third ventricle CSF.  In the mare, some 
investigators have been able to successfully measure episodic release of LH and GnRH 
[47]. A high correlation between GnRH and LH pulses were reported using the ICS 
technique [15,32,47,48].  Irvine, Alexander [49] reported that 90% of LH peaks were 
concurrent with GnRH peaks. Our group applied this technique to evaluate possible 
changes in GnRH that might be indicative of seasonal regulation of gonadotropins.  
Surprisingly, we were unable to find any aspect of GnRH secretion that differed during 
the four seasons [16].   
Many of the methods used to increase LH and hasten the onset to first ovulation 
have been shown or proposed to act through the increased frequency or amplitude of 
GnRH release from the hypothalamus [35,47].  Numerous trials administering 
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exogenous, native GnRH or GnRH agonist, demonstrate that by increasing circulating 
concentrations  of GnRH, mean circulating concentrations of LH increase markedly and 
this increase is capable of initiating ovarian cyclicity in anovulatory mares [50-54].  
 
2.6  RFamide-related peptides  
In the past decade, research has identified a group of peptides in the RF-amide 
related peptide super family of peptides shown to play a major role in regulating the 
secretion of LH and controlling seasonal reproduction in avian species.  In the latter, the 
RFRP-3 sequence has been given the name, GnIH, and its homologue may play a similar 
role in seasonal-breeding mammalian species and evidence suggesting participation in 
estradiol feedback [9,55,56].  RF amide-related peptides, RFRP-1 and RFRP-3, the 
mammalian homologs of avian GnIH, are shown to be highly conserved inhibitory 
neuropeptides among bird and mammals [57]. GnIH was first isolated from the brain of 
Japanese quail and shown to cause a dose dependent inhibition of LH secretion from 
avian pituitary cell cultures [55,58].  Since this study, variations of this neuropeptide 
have been identified in both birds and mammals, with GnIH-RP-1/RFRP-1, GnIH-RP-
2/RFRP-2, and RFRP-3, all having affinity for the receptor, GPR-147 and to a lesser 
extent GPR-74 [57,59].  
The small peptide, RF9, or 1-adamantanecarbonyl-RF-NH2, was discovered by 
Simonin et al.[60] while searching for a receptor antagonist of neuropeptide FF (NPFF).  
The latter is an endogenous neuropeptide shown to modulate the hyperanalgesic effects 
of opioids, leading to an increased sensitivity to pain due to extended exposure to 
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opioids.  The RF9 peptide proved to have a significant affinity for NPFF receptors, 
NPFFR1 (GPR-147) and NPFFR2 (GPR-74) and was able to reduce the hyperanalgesic 
effect in rats when co-administered with heroin during a paw-pressure vocalization test 
[60].  Our interest in RF9 is based on its ability to stimulate or disinhibit the release of 
gonadotropic hormones.     
Since the identification of GPR-147 as the RFRP receptor and the discovery of 
RF9, a number of investigations have sought to determine the mechanisms behind their 
ability to modulate hypothalamic and pituitary secretions.  The common theme among 
much of the research investigating RF9 is that it has been shown to reliably increase in 
vivo secretion of LH across various species, including mice [61], rats and hamsters [62], 
sheep [63], and horses [64] following either peripheral and/or intracerebroventricular 
(ICV) injection. Although responses are consistent, the mechanism underlying the effect 
of RF9 has not been definitively elucidated. While it is assumed that RF9 stimulates 
release of hypothalamic GnRH, direct pituitary effects have not been ruled out.  
Evaluation of the effects of RF9 on secretion of LH from hemipituitary explants (Pineda, 
et al. [61] revealed no direct effect of RF9 in the absence of GnRH.  Li, et al. [65] 
reported an increase in LH from swine anterior pituitary cell cultures exposed to RFRP-3 
and GnRH, when treated with RF9. In similar studies with sheep, the apparent role of 
GnRH mediating the effects of RF9 was evident. In that study RF9 elicited release of 
LH, but when RF9 was administered in conjunction with Teverelix, a GnRH antagonist, 
LH release was blocked [63]. This indicates that the mechanism of action of RF9 is 
likely upstream of the adenohypophysis and mediated primarily at the hypothalamus 
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through release of GnRH. Recent neuronal investigations in mice have shown that RF9 
increases the firing rate in 70% of GnRH neurons [66]. However, by using genetically 
modified kisspeptin receptor (Kiss1r)-null mice the group also concluded that RF9 acts 
directly on GnRH neurons and contrary to much of the earlier work is dependent upon 
Kiss1r [66].  Although the mechanisms through which RF9 elicits its effects is still 
unclear, evidence suggests that it is acting directly or indirectly on GnRH neurons to 
increase gonadotropins.    
 
2.7  Estradiol 
 The gonadal steroid, estradiol, regulates seasonal changes in the secretion of LH 
in the ewe through both steroid-dependent and steroid-independent systems [67]. In the 
ewe, increased estradiol negative feedback during the non-breeding season and changes 
in dopaminergic tone reduce the pulse frequency in tonic secretion of LH [67-69]. As 
stated above, this model has been tested in the mare with inconsistent results. In the 
mare, estradiol may play an important role in the transition from the anovulatory season 
to the breeding season by stimulating the production and secretion of LH [10,11,70]. 
Estradiol is at basal concentrations throughout the mid-anovulatory period and transition 
period [70]. Prior to first ovulation, preovulatory follicles gain steroidogenic competence 
and circulating estradiol concentrations begin to rise followed by a similar increase in 
circulating LH concentrations, leading up to the LH surge and ovulation [70,71]. Sharp, 
et al. [10] demonstrated that chronic treatment with estradiol in ovariectomized mares 
for 16 d in the early transition period will increase circulating LH. Similar research in 
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estrus mares treated with estradiol-17β immediately before GnRH treatment proved to 
effectively increase LH concentration when compared to treatment of GnRH alone, 
suggesting a facilitative effect from estradiol [72]. However, in contrast to Sharp, et al. 
[10], Mumford, et al. [73] was unable to show any significant increase in circulating 
concentrations of LH in early transitional mares during chronic treatment with estradiol 
or estradiol plus a GnRH agonist but showed an increase in releasable LH in the latter 
when challenged with GnRH following the treatment period.  Earlier research that 
examined the effects of chronic treatment with estradiol-17β (10 mg/d) during the 
breeding season reported inhibition of follicular development, while showing serum 
concentration of LH to be increased during the follicular phase. Treatment resulted in an 
extended interovulatory interval with ovulation occurring 2 to 3d following the last 
estradiol injection [74,75]. This data suggests that estradiol may act to increase synthesis 
or secretion of LH or increase LH responsiveness to GnRH treatment in the ovulatory 
and transitional mare, but results are not clear, leaving questions particularly in the 
winter anovulatory mare. 
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CHAPTER III 
HYPOTHALAMIC-HYPOPHYSEAL RESPONSIVENESS TO A PUTATIVE 
NEUROPEPTIDE FF RECEPTOR ANTAGONIST, RF9 IN THE MARE 
DURING THE BREEDING SEASON AND MODULATION OF ITS EFFECTS 
BY ESTRADIOL DURING THE WINTER ANOVULATORY PERIOD 
 
3.1  Introduction 
 For the majority of the mare population, the seasonal cessation of ovarian 
cyclicity occurs around the winter solstice and recrudescence of ovarian cyclicity 
resumes after the spring equinox [1].  However, the majority of equine breed registries 
maintain a universal birthdate of January 1 in the Northern hemisphere [1].  This 
incongruence has led professional horse breeders to adopt supplemental lighting 
programs to advance the operational breeding season in an effort to advance foaling 
dates as close to the established annual birthdate as possible [4,76], and thus to provide 
offspring a maturational advantage at least through 3 yr of age [2,3].    
Physiological mechanisms associated with the photoperiodic control of 
seasonality in the mare have been reviewed extensively [1,5,9].  The primary 
gonadotropic factor associated with the seasonal occurrence and recrudescence of 
ovarian cyclicity is luteinizing hormone (LH), and hypothalamic signaling pathways that 
regulate the secretion of LH in the mare have been described [1,13,16,70].  Several of 
these have been examined for their potential as pharmacological targets to accelerate 
resumption of anterior pituitary secretion of LH during the winter anovulatory period 
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and thus to expedite reproductive transition [9]. The most common approach has 
involved the exogenous application of GnRH and GnRH agonists to directly stimulate 
adenohypophyseal synthesis and secretion of LH. 
During the last 10 yrs., an entirely new neuroendocrine signaling pathway 
involving a family of RF amide-related peptides (RFRP) associated with gonadotropin 
secretion and seasonal breeding in avian species has been described [58,77,78]. One of 
these, RFRP3 has now been named gonadotropin inhibitory hormone (GnIH).  
Homologs of GnIH also exist in mammals, including the horse [64]. The most 
prominently active of these, RFRP3 has been shown to inhibit secretion of LH in several 
mammalian species [58,77,78].  The first evaluations of GnIH and its putative 
antagonist, RF9 in the horse were reported recently by our group [8].  Results from these 
studies, as well as those obtained from several other species, suggest that RF9 may have 
a prospective role as a pharmaceutical means of stimulating secretion of LH 
[9,63,64,78]. However, additional characterization of hypothalamic and pituitary 
responses to RF9 is required in order to more fully understand its biology and to 
appreciate its potential as a pharmacological agent, including the role of ovarian steroids 
in modulating hypothalamic responses to RF9.  Therefore, the objectives of the studies 
reported here were to test the hypotheses that 1) RF9 stimulates secretion of GnRH in 
concert with secretion of FSH and LH, thus confirming a hypothalamic site of action, 
and 2) estradiol modulates hypothalamic responsiveness to RF9. 
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3.2  Materials and Methods    
 The Institutional Agricultural Animal Care and Use Committee of the Texas 
A&M University approved in advance all procedures used in this study. 
 
3.2.1  Experiment 1. Hypothalamic-adenohypophyseal responsiveness to RF9 during the 
mid-luteal phase of the estrous cycle    
3.2.1.1 Animals 
 Sixteen light horse mares, predominantly American Quarter Horses, were 
maintained on a pasture of mixed grasses and supplemented with Coastal Bermuda grass 
hay as needed to maintain a body condition score of 5 to 6 (1 to 9 scale) [79] at the 
Texas A&M AgriLife Research Station in Beeville, TX.   
 
3.2.1.2  Experimental procedures 
Mares were assigned randomly to one of two treatment groups: 1) control (n = 8) 
or 2) RF9 (n = 8).  The experiment was conducted during the breeding season (Aug. 6-
21). All mares were examined by transrectal ultrasonography (Honda HS-feb500V, 
Honda Electronics Co., LTD) every 1 to 3 d for approximately 3 wk prior to the start of 
the study to assess ovarian status. Estrous cycles were synchronized by regression of a 
functional corpus luteum (CL) using prostaglandin F2-alpha (PGF2α).  Following 
PGF2α treatment, ovarian follicular populations were evaluated at 1- to 2-d intervals 
until ovulation. Treatments were initiated on day 7 to 10 following ovulation. Fifteen 
minutes prior to treatment, all mares received Regu-Mate® (0.044 mg/kg; DPT 
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Laboratories, San Antonio, TX) to inhibit the occurrence of large LH pulses associated 
with the luteal phase. Twenty-four hours before treatment, mares were fitted with   
intercavernous sinus (ICS) and jugular catheters for intensive blood sampling. The 
internal end of the ICS catheter was placed in close proximity to pituitary effluent based 
on the relationship of catheter length to facial anatomy as reported previously by our 
group [80,81].  Mares in the treatment group received intravenous injections of RF9 
(GeneCust Europe, Dudelange, Luxembourg) in saline at times 30 and 90 min using 
doses of 0.2 and 0.4 mg/kg BW, respectively. Doses were based on our previously 
reported studies [64]. Control mares were treated similarly with saline. Blood samples 
were collected from both the ICS (3-5 mL) and jugular catheter (10 mL), beginning 30 
min before treatment and continuing at 10-min intervals for 6 h. 
 
3.2.1.3  Intercavernous sinus catheterization  
 Catheterization of the intercavernous sinus (ICS) was performed following 
procedures described previously [46,48,80,81]. The mare was placed in a stock and 
sedated with detomidine HCL (Dormosedan®, 20-40 µg/kg BW; Pfizer. New York, 
NY). The facial vein lies parallel to and along the anterior border of the mandible. An 
area centered over this line and extending in all directions for approximately 2 to 2.5 cm 
was clipped, scrubbed and disinfected for aseptic surgery. The facial vein was detected 
by palpation and an area (approximately 1 cm x 1cm) overlying and surrounding the 
vein, but below the facial crest, was infiltrated subcutaneously with 2% lidocaine HCL 
(Vedco, Inc, St Joseph, MO). A 1-cm skin incision was made over the vein, and the vein 
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exteriorized with blunt dissection and held in the exteriorized position by placing a 
sterile probe or rod between it and the underling tissue. A small cut was made in the vein 
while occluding flow and a Tygon® catheter (0.04 i.d. x 0.07 o.d.; Norton Performance 
Plastics Co, Akron, OH) was inserted into the vein. A flexible stylette was maintained in 
the catheter, and the catheter was gently threaded up the vein to a predetermined distance 
based on past procedures where radiographic imaging was used to confirm the location. 
If resistance was felt before reaching the predetermined distance the catheter was 
withdrawn to a point prior to the resistance. The objective was to thread the catheter 
cranially to the base of the cranial cavity. Once in place, the stylette was removed and 
blood flow was confirmed. If the catheter did not flow it was adjusted until flow was 
confirmed and a heparin (10,000 IU/mL) lock was placed in the tubing. The tubing was 
sutured in place with synthetic sutures (Supramid®; S. Jackson, Inc., Alexandria, VA) 
and the skin closed and dressed with an antiseptic skin dressing. During ICS blood 
sampling, the mares received 30,000 IU heparin i.v. every 3 h.  
 
3.2.1.4  Blood collection and processing 
 On the day of sampling, mares were heparinized using 30,000 IU of heparin i.v., 
loosely tied, and provided hay and water for the duration of the collection period. An 
additional 30,000 IU of heparin was administered 3 h after onset of sampling. Sterile 
saline (5 mL) was used to flush catheters after each blood sample and 5 mL saline 
containing 1,000 IU of heparin was used to flush catheters hourly. Jugular samples were 
placed in tubes containing 50 µL 5% EDTA-heparin solution (10,000 IU/mL). The ICS 
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collection tubes also contained 50 µL 5% EDTA-heparin solution and an additional 100 
µL of a 50 mM solution of bacitracin (Sigma Chemical co., St. Louis, MO, USA) to 
minimize metabolism of GnRH [47]. Upon collection, the tubes were immediately 
placed on ice and centrifuged (562 x g) for collection of plasma every 30 min. Plasma 
was stored at -20°C until hormone analysis for concentrations of LH, FSH (jugular 
samples) and GnRH (ICS samples). 
 
3.2.2  Experiment 2. Effects of estradiol pretreatment on hypothalamic-
adenohypophyseal responsiveness to RF9 in winter anovulatory mares  
 
3.2.2.1  Animals 
 Ten light horse mares, predominantly American Quarter Horses, were maintained 
on a pasture of mixed grasses and supplemented with Coastal Bermuda grass hay as 
needed to maintain a body condition score of 5 to 6 (1 to 9 scale) [79] at the Texas A&M 
AgriLife Research Station in Beeville, TX. 
 
3.2.2.2  Experimental procedures  
 Ovulatory status was monitored using transrectal ultrasonography (Honda HS-
Feb500V, Honda Electronics Co., LTD), starting 4 wk prior to the start of the study.  
Mares were confirmed anovulatory based on the absence of a corpus luteum (CL), and 
no follicle > 30mm. Only 2 of 10 mares had follicles > 20 mm at the start of the study.  
Mares were stratified by largest follicle and assigned randomly to one of 2 treatment 
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groups 1) Control-RF9 [single i.m. injection of 2 mL corn oil followed 18 h later by i.v. 
injection of RF9 (0.4 mg/kg BW); n = 5], or 2) Estradiol-RF9 [single i.m. injection of 2 
mL corn oil containing 5 mg estradiol-17β followed 18 h later by i.v. injection of RF9 
(0.4 mg/kg BW); n = 5]. Treatment initiation was staggered over 2 consecutive d, with 
an equal number of mares in each group divided between the 2 d. The peptide, 1-
adamantanecarbonyl-RF-NH2 (RF9; > 95 % purity) was obtained from American 
Peptide Company, Vista, CA. Mares were fitted with a jugular catheter at the time of 
corn oil/estradiol treatment, approximately 18 h before intravenous RF9 administration. 
Blood samples were collected from the jugular catheter at 15-min intervals starting 30 
min before RF9 treatment and continuing for the first 2.5 h. Sampling frequency was 
then reduced to 30-min intervals for the final 3 h. Jugular catheters were removed 
immediately after intensive sampling. 
 
3.2.2.3  Blood collection 
 On the day of intensive sampling, mares were tied loosely and provided hay and 
water for the duration of the collection period. The catheter was flushed following each 
sample as described previously (3.2.1.4). Samples were placed in tubes containing 50 µL 
5% EDTA-heparin solution (10,000 IU/ML) to assure that samples did not coagulate. 
Upon collection, the tubes were immediately placed on ice and centrifuged (562 x g) for 
collection of plasma every 30 min. Plasma was stored at -20°C until hormone analysis 
for concentration of LH. 
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 3.2.3.  Hormone analysis     
 Plasma concentrations of LH and FSH were assayed in triplicate utilizing double 
antibody RIAs and GnRH was assayed in duplicate utilizing a single extraction as 
validated previously in this laboratory [16,82]. A highly purified equine LH preparation 
(LH AFP-5130A) was used for both iodinated tracer and reference standards in 
conjunction with anti-equine LH antiserum (AFP-240580) at a dilution of 1:120,000. A 
highly purified equine FSH (eFSH AFP-5022B, eFSH AFP-8830D) preparation was 
used for the iodinated tracer and standards in conjunction with anti-eFSH antiserum 
(AFP-2062096) at a dilution of 1:12,500. Highly-purified hormones and antisera were 
provided by Dr. A.F. Parlow, National Hormone and Peptide Program (NHPP), Harbor-
UCLA Research and Education Institute, Los Angeles, CA. The sensitivity, intra- and 
interassay coefficients of variation (CV) for Exp. 1 were 0.25 ng/mL, 7.6% and 10.0%, 
respectively for LH, and 0.5 ng/mL, 5.1% and 3.7%, respectively for FSH. For Exp. 2, 
the sensitivity, intra- and interassay-CV were 0.25 ng/mL, 9.5% and 5.6%, respectively 
for LH. 
The GnRH assay for Exp. 1 could not be validated. Therefore, no GnRH data are 
presented and the hypothesis related to secretion of this specific hormone could not be 
tested. 
 
3.2.4. Statistical analysis 
 Analysis of repeated measures was used to determine main effects of treatment 
on temporal changes in serum hormone concentration and estrous behavior utilizing a 
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mixed model procedure of the JMP program associated with Statistical Analysis Systems 
(SAS; SAS Inst., Inc., Cary, NC). The model included LH- and/or FSH-dependent 
variables, using day as the within subject factor, treatment as the between-subject factor, 
and mare as the subject. Fixed effects were treatment, day, and treatment x day 
interaction. In Exp 1, only mares with successful ICS cannulations were used in the trial 
(Control, n = 6; RF9, n = 7). In Exp 2, all mares were used in the analysis (Control-RF9, 
n = 5; Estadiol-RF9, n = 6). If fixed effects were found significant, a pair-wise 
comparison was performed using least squares means Student’s t-test.  Main effects were 
considered significant when P ≤ 0.05 and a trend toward significance when P ≤ 0.10 
 
3.3  Results 
3.3.1 Experiment 1. Hypothalamic-adenohypophyseal responsiveness to RF9 during the 
mid-luteal phase of the estrous cycle 
Mean concentrations of LH and FSH did not differ among groups during the 
pretreatment period (-30 to 0 min.); however, within 20 min following the first injection 
of RF9 (0.2 mg/kg BW), circulating concentrations of LH and FSH had both increased 
(P < 0.05 and P < 0.04, respectively) above the control (Fig. 3.1). Circulating LH 
concentrations increased to a maximum mean concentration 40 min following the second 
bolus treatment of RF9 (0.4 mg/kg BW), with a mean peak difference from the control 
of 1.2 ± 0.3 ng/mL (P < 0.003). Follicle stimulating hormone demonstrated a similar 
response but reached a maximum mean concentration at 30 min following the second 
bolus treatment of RF9, with a mean peak difference from the control of 4.3 ± 1.4 ng/mL 
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(P < 0.0003).  Response curves for both LH and FSH demonstrated a similar linear 
decay from peak concentrations and reached pretreatment concentrations by the end of 
the 6-h blood sampling period. The overall treatment effect on mean concentrations of 
LH and FSH following the initiation of RF9 treatments were greater (P < 0.05 and P < 
0.02, respectively) in RF9-treated than in control mares. A treatment x time interaction 
(P < 0.001) was noted for both hormones, with hourly means differing as depicted in 
Fig. 3.1.   
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Fig. 3.1.  Least squares mean concentrations of LH (A) and FSH (B) over the 6-h 
sampling period in Control (dashed line; n = 6) and RF9-treated (solid line; n = 7) mares. 
Arrows denote RF9 or saline treatments at time 0 (RF9 = 0.2 mg/kg BW) and 60 (RF9 = 
0.4 mg/kg BW) min, respectively. LH and FSH Treatment x time P < 0.0001. 
 
3.3.2 Effect of estradiol pretreatment on hypothalamic-pituitary responsiveness to RF9 
in winter anovulatory mares 
  Mean concentrations of LH did not differ between groups during the 
pretreatment period (-30 to 0 min). Concentrations of LH in both Control-RF9 and 
Estradiol-RF9 increased (P < 0.02; P < 0.0001 respectively) following RF9 treatment, 
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with maximum concentrations of LH observed at 30 min following RF9 injection (Fig. 
3.2.). Although the overall mean concentrations of LH did not differ for the 5-h post-
treatment period, there was a treatment x time interaction (P < 0.04). The mean peak 
concentration of LH occurring at 30 min post-treatment was greater (P < 0.05) in 
Estradiol-RF9 treated than in Control-RF9 treated mares. 
 
 
Fig. 3.2.  Least squares mean concentrations of LH in the Control-RF9 (dashed line) and 
Estradiol-RF9 (solid line)-treated mares. Mares were treated at time 0 min and mean 
concentrations of LH did not differ during the pretreatment period (-30-0 min). 
Differences are indicated by (*) P < 0.05. Treatment x time P < 0.04 
 
3.4  Discussion 
 Confirmation that RF9 stimulates the secretion of GnRH from the hypothalamus, 
based on in vivo experiments, has not been reported. One of the objectives of studies 
reported herein was to address this question using the ICS cannulation technique in the 
mare. This approach facilitates measurement of pituitary, and potentially, hypothalamic 
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hormone secretion by sampling pituitary venous effluent. Unfortunately, this objective 
was not met in the current work due to the inability to validate measurement of GnRH in 
ICS plasma. However, the blockade of RF9 mediated release of gonadotropins by GnRH 
antagonists suggests a GnRH-dependent effect in the ewe and the mouse [62,63].  
Moreover, the putative RF9 receptor, GPR147, has been identified on GnRH and 
kisspeptin neurons in the rostral paraventricular region of the hypothalamus. In contrast, 
recent investigations using the Kiss1receptor (Kiss1r)-null mouse suggest that RF9 is 
acting on GnRH neurons through activation of Kiss1r [66]. These and similar 
observations have led to increasing recognition of RF-amide related ligands cross 
reacting with several receptors [83].  
Results of the current experiments confirm the ability of RF9 to reliably increase 
circulating concentrations of LH in the mare during both the winter anovulatory period 
and natural breeding season. We also show for the first time the ability of RF9 to 
stimulate secretion of FSH in the mare in a manner that mirrors that of LH, with no 
indication of differential responsiveness. Earlier reports in the ewe have shown a similar 
response [63]. While Exp. 1 and 2 were not designed to compare seasonal responses, it is 
obvious that RF9-mediated secretion of LH is greater during the breeding season 
compared to the non-breeding season. This is readily explained in the mare by the fact 
that pituitary content of LH during the winter anovulatory period is markedly depleted 
relative to the breeding season [18,84]. Thus, it is expected that the ability of the anterior 
pituitary to release LH in response to any secretagogue would be compromised in the 
mare during the non-breeding season. However, this is in contrast to observations in the 
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seasonal breeding ewe, where the lesser response is observed during the breeding 
season. Pituitary content of LH is not depleted during the anestrous season in ewes. 
Thus, pituitary content and RF9 responsiveness are lower during the breeding season of 
the ewe due to greater depletion of LH coincident with a greater rate of endogenous 
secretion [63].  
The gonadotropic response to RF9 has been well established by our group and 
others across several mammalian species including the horse, rodents, and sheep [61-
64]. In the current study, we have expanded this information by examining the ability of 
the ovarian steroid hormone, estradiol-17β to modulate RF9 responsiveness during 
winter anovulation. Results indicate that estradiol pre-treatment enhanced the response 
to RF9, with mean LH peak greater following treatment with RF9. The effect of 
estradiol in the mare during the transition from winter anovulation to first annual 
ovulation has not been well characterized. However there is evidence that LH synthesis 
is increased in ovariectomized mares during vernal transition [11].  In seasonal breeding 
sheep, estradiol treatment has been shown to increase the number of GnRH receptors on 
gonadotropes [85]. Although not examined directly in the mare in response to estradiol, 
concentrations of anterior pituitary GnRH receptors were reported to be unchanged 
during different stages of the estrous cycle [18]. However, a decrease in pituitary content 
of GnRH receptors has been reported in the mare during the seasonal anovulatory period 
compared to the breeding season [43]. If estradiol is upregulating the GnRH receptor in 
the mare, and RF9 stimulates GnRH release, this may explain why a similarly-enhanced 
response is seen with direct treatment with GnRH [86]. 
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Estradiol has been reported to downregulate the expression of RFRP in the 
mouse, suggesting a decrease in inhibition of GnRH neurons [56]. This could account 
for the ability of estradiol to enhance RF9’s stimulatory effects in the current work. 
Although there remains uncertainty regarding the mechanism of RF9’s primary action 
through GPR147, RFRP3’s affinity to the receptor has been supported [66,87]. In fact, in 
the GPR147-null mouse, RFRP3 was unable to suppress  serum concentrations of LH 
[87]. Although our group has been unable to demonstrate in vivo or in vitro (via pituitary 
cell culture) inhibition of LH secretion in the mare following treatment with RFRP3, we 
have confirmed the RFRP3 machinery is present in the mare, including presence of 
hypothalamic neurons immunoreactive for RFRP3 and anterior pituitary expression of 
the NPFFR receptor [64,88]. Also, as indicated earlier, RF9 can act through direct 
activation of GPR54. Thus, estradiol could exert its affects through increased expression 
of GPR54 in GnRH cells as seen in cultured GT1-7 GnRH cells following 24 h exposure 
to estradiol.  
In conclusion, the results from the current experiments confirm the ability of 
RF9, a putative RFRP-3 receptor antagonist, to increase circulating concentrations of LH 
during both the breeding and non-breeding seasons of the mare in concert with a similar 
ability to stimulate release of FSH. These and other related reports suggest that RF9 
creates these effects by stimulating the release of GnRH from the hypothalamus. 
However, we were not able to confirm this in the current work. We have also 
demonstrated that estradiol may enhance responsiveness to RF9 but the location of 
action of this effect remains to be determined. 
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CHAPTER IV 
DEVELOPMENT OF A LIQUID CHROMATOGRAPHY/MASS 
SPECTROMETRY PROTOCOL TO QUANTIFY METABOLIC 
CLEARANCE RATE OF EXOGENOUSLY-ADMINISTERED RF9 IN THE 
MARE 
 
4.1 Introduction 
 Previous studies have shown that low peripheral plasma concentrations of LH 
serve as the primary basis of ovarian quiescence during the non-breeding season in the 
mare [13]. Low circulating LH occurs as a consequence of reduced secretion of GnRH 
and appropriate treatment of seasonally anovulatory mares with GnRH increases LH and 
can restore ovulatory cycles [53,89]. A potential role for RF amide‐related peptides in 
regulating seasonality in horses has been proposed to cause a decrease in GnRH release 
that is accompanied by a decrease in downstream release of LH [9]. Similarly, RF9, a 
putative RFRP receptor signaling antagonist, has been shown to stimulate the release of 
LH in several mammalian species, including the winter anovulatory mare [8,61,63]. It is 
of interest, therefore, to characterize the pharmacological potential of RF9 in this setting. 
The objectives of this experiment were to develop a means of quantifying RF9 using 
liquid chromatography/mass spectrometry (LC/MS) and to use this approach for 
assessing the rate of disappearance of exogenously-administered RF9 in the mare. 
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4.2 Materials and Methods 
 All animal-related experiments were approved by the Institutional Agricultural 
Animal Care and Use Committee (IAACUC) of the Texas A&M System. 
   
4.2.1 Experimental procedures 
 The plasma used for the blanks were from a single mare that had not been 
exposed to RF9 and was stored at -20°C. Plasma samples used for this assay were from 
previous work conducted by Thorson, et al. [8]; 5 RF9-treated mares and 3 Controls or 
non-treated mares. Blood samples obtained in Thorson’s research were collected over 6 
h and drawn from an indwelling intravenous jugular catheter at 10-min intervals (Fig. 
4.1.).  The RF9 was administered at a dose of 0.4 mg/kg body weight at 60 min and 120 
min after intensive sampling was initiated to evaluate secretion of LH from the anterior 
pituitary. Samples were placed into tubes containing 50 µL ethylenediaminetetraacetic 
acid-heparin solution to prevent coagulation and placed directly on ice. Every hour post-
harvest, samples were processed by centrifugation for plasma collection and stored at -
20°C until thawed for determination of concentrations of LH by RIA. Following the LH 
RIA assay, plasma was again stored at -20°C until briefly thawed for LC/MS evaluation 
of RF9 concentrations in peripheral circulation. For the purposes of our assay, we chose 
samples prior to treatment (t = 50 min) and samples immediately following treatment (t 
= 70, 130 min). To evaluate its half-life, we chose samples 140 min and 240 min 
following the last treatment based on earlier evaluation in sheep reporting a 2.1 h 
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terminal half-life [63]. The non-treated mares (negative controls) were used to evaluate 
if there are biological factors in regular plasma that would lead to a false positive. 
 
 
Fig. 4.1. Time line of sampling with red arrow heads indicate time points used in the 
current study. 
 
 
4.2.2 Preparation of standards 
The stock solution was first prepared by dissolving 1 mg of RF9 in 1 mL 
methanol. Then the concentrated methanol was diluted 500 fold to make 5 mL of stock 
solution at 2 µg/mL. The stock solution was then stored at -20° C and thawed prior to 
preparation of calibration standards and stored in ice while dilutions were being made. 
The internal standard (I.S.), testosterone-D3 (16, 16, 17-D₃) in stock solution was 
at 100 µg/mL in acetonitrile and stored at -20°C. Testosterone –D3 was added to water, 
acetonitrile, and formic acid (89.9:10:0.1 v/v) to make the resuspension solution daily at 
100 ng/mL and volume varied based on number of samples being analyzed that day.   
Calibration standards were made daily by first spiking 190 µL of PBS with 10 
µL of the stock solution to create 200 µL of working solution (100 ng/mL).  Dilutions 
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were made by spiking 100mL of PBS with the working solution to the desired 
concentrations 2, 5, 10, 20, 50, 80, 100 ng/mL and the 300, 500, 1000, 2000 ng/mL 
standards made by spiking 100 µL PBS with the stock solution. Then 100 µL of blank 
plasma was added to each vial, vortexed for 30 s, and allowed to equilibrate for 2 min 
before extraction. The calibration standards were then extracted with the analysis for that 
day using the following extraction method. 
 
4.2.3 Sample extraction   
One-hundred microliter aliquots of plasma from 8 mares (non-treated, n = 3;  
RF9 treated, n = 5) or calibration standard in blank plasma was added to a 1.5-mL 
Eppendorf-style tube and diluted with 100 µL of PBS, mixed for 30 s and allowed to sit 
on ice for 2 min. Five-hundred microliters of acetonitrile with 0.1% formic acid was 
added to each tube, mixed for 30 s and allowed to sit on ice for an additional 2 min 
before centrifugation at 9447 x g for 15 min.  After centrifugation, 400 mL of the 
aqueous supernatant fluids were transferred into a clean 1.5-mL Eppendorf-style tube 
and dried using vacuum centrifugation (SpeedVac). An additional 40 uL of the extract 
supernatant was removed for the time 70 and 130 samples to create 10-fold dilutions, 
ensuring they would fall within the measurable range of the assay. The dried samples 
were then dissolved in 100 µL of reconstitution solution containing the internal standard, 
mixed for 30 s and for an additional 10 min in a sonicated water bath. The tubes was 
then centrifuged again at 9447 x g for 10 min and 50 µL of the supernatant fluids were 
transferred to an autosampler vial, taking care not to disturb the precipitant pellet. The 
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samples were loaded into a chilled drawer of the Accela auto-sampler cabinet.  An 
aliquot of 20 µL was injected into the LC/MS system for analysis. 
 
4.2.4 Chromatographic conditions  
All chromatography was performed on an Acclaim Polar II C18 column (3 µm, 
2.1 x 50 mm, ThermoScientific) operating at room temperature. Both RF9 and 
testosterone-D3 were tuned separately for optimum sensitivity. The method was then 
developed to incorporate the optimal chromatographic conditions for both substrates. 
 
4.2.5 Mass spectrometry conditions  
Mass spectrometry was performed by use of an Exactive Orbitrap mass 
spectrometer (ThermoScientific, San Jose, CA) equipped with a heated electrospray 
ionization source operating in positive mode. Nitrogen was used as sheath, auxiliary and 
sweep gases. Different parameters were used for RF9 and Testosterone-D3 to optimize 
sensitivity for each substance.  Method development and data acquisition was performed 
with Trace Finder v3.1 (ThermoScientific).  
 
4.2.6 Pharmakinetic analysis 
The means of the 5 treated mares following the last RF9 treatment (t = 130, 260, 
360) were evaluated using PKSolver 2.0, a pharmakinetic and pharmacodynamics data 
analysis add-in for Microsoft Excel [90]. The analysis was done using the non-
compartmental approach for plasma after intravenous bolus input.  
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4.3 Results 
 The quantitative recovery of RF9 from equine plasma was demonstrated and by 
utilizing Trace Finder v3.1 (ThermoScientific) we also demonstrated a standard 
calibration curve for RF9 that was linear (r2 = 0.999) over the concentration range of the 
assay (2  to 2000 ng/mL) using a weighted least square linear regression analysis with a 
weighing factor of 1/X (Fig. 4.2.). The representative regression equation for the 
calibration curve was y = 8.158e-8x² + 5.29e-3. The lower limit of detection for the 
assay was 2 ng/mL, with the lower limit of quantification designated at 20 ng/mL. The 
intra-assay CV of the assay determining RF9 concentrations in the mares evaluated was 
3.8%. The negative controls did present low levels of detection with a maximum range 
from 0 to 9.3 ng/mL with a mean (± SEM) of 2.0 ± .6 ng/mL. Analysis of RF9 
circulating concentrations in the mare proved to have a rapid increase following 
treatment and also expressed a rapid decline following treatment (Fig. 4.3.) with a 
predicted clearance rate (CL) of 0.000912 mg/(ng/mL)/min and half-life (t1/2) 40 min 
calculated from the mean CL of RF9 from the five treated mares (Fig. 4.4.). 
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Fig. 4.2. Linearity was determined to assess the performance of the method. A least‐
squares regression fit to a quadratic equation with a weighting index of 1/X order was 
performed on the peak area ratios of RF9 and I.S. versus RF9 concentrations of the ten 
plasma standards (2, 5, 10, 20, 50, 100, 300, 500, 1000 and 2000 ng/mL) in duplicate to 
generate a calibration curve. 
 
 
 
Fig. 4.3. RF9 in equine plasma. A) RF9 in five treated mares. B) Average of the five 
treated mares including the average of the three non-treated mares. Error bars represent 
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Fig. 4.4. Half-life was calculated using the mean plasma concentrations of last three time 
points. PKSolver was used in a non-compartmental analysis of plasma following bolus 
i.v. infusion. (t1/2 = 40 min) 
 
4.4 Discussion 
 The results from previous work by our group has proven RF9 to be a reliable 
means of pharmacologically increasing circulating concentrations of LH in cyclic and 
acyclic mares [8,64] (Korthanke unpublished). Because of RF9’s reliability to increase 
LH, a pharmacokinetic evaluation of its half-life in the circulatory system of the mare 
was warranted to allow for further investigation of its practical application as a 
pharmacological agent through various dose regiments. Results indicate that we were 
able to successfully extract RF9 from equine plasma and develop an accurate means to 
quantify its presence in plasma using an LC/MS method that allowed further evaluation 
of its elimination from the blood over time. Using the cumulative average of all the 
mares, we showed that within 4 h RF9 has been eliminated from the circulation to a 
point near the LLOQ for our assay. Using the PKSolver application provided by 
Microsoft Excel, we were able to determine the t1/2 and predicted CL of RF9 in the 
mare for further dosage calculations.   
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 Because of the dose required to obtain a significant gonadotropic response to 
RF9 in an animal as large as the horse, and metabolic clearance data presented here, it 
appears unlikely that RF9 could be used chronically to stimulate secretion of 
gonadotropins in the equine species under practical conditions. Employing methods used 
previously by our group (e.g., Alzet Osmotic Pumps; DURECT Corp., Cupertino, CA) 
and the solubility of RF9, it appears it would be impossible to program effective delivery 
over extended periods of time because of the small maximum volume and flow rate of 
these pumps. 
 In conclusion, we were able to develop a method to extract and quantify RF9 
from equine plasma for further pharmacological investigations. Results indicated that the 
pharmacological application of RF9 may be limited in horses to acute treatment because 
of its short half-life and limitations in availability of delivery platforms for continuous 
applications.    
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CHAPTER V 
ESTRADIOL AND ITS INTERACTION WITH GnRH IN REGULATING 
SECRETION OF LH IN WINTER ANOVULATORY MARES DURING 
INCREASING PHOTOPERIOD 
 
5.1 Introduction 
The mare is a seasonal long-day breeder with approximately 85% becoming 
anovulatory by the time of the winter solstice. Seasonal recrudescence of ovarian 
cyclicity occurs after the spring equinox coincident with increasing day length [2]. The 
onset of the seasonal anovulatory period is characterized by a marked decline in 
circulating concentrations of LH that precedes the arrest of ovulatory cycles. Similarly, 
the resumption of reproductive cyclicity occurs as a consequence of a marked increase in 
synthesis and secretion of LH. Reproductive periodicity in seasonal species is 
synchronized by environmental cues and, in the mare, day-length is the primary 
environmental factor influencing reproductive patterns. While many of the physiological 
mechanisms underlying seasonal reproduction have been characterized, a full 
understanding of these mechanisms, particularly in the horse, remains lacking [9].  
Vernal transition usually begins during increasing photoperiod around the time of 
the spring equinox and includes increased secretion of LH and ovarian follicular 
development. Associated with this activity is an increase in estradiol secretion as 
follicles gain steroidogenic competency [70,71]. Some previous reports indicate that 
estradiol is stimulatory to the reproductive neuroendocrine system in the mare and 
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increases secretion of LH [10,11,91]. Notable examples include the occurrence of foal 
heat in mares foaling during the winter [92,93] and in response to treatment with 
estradiol during increasing photoperiod [10,11]. However, reports on changes in 
secretion of LH in response to exogenous estradiol during increasing photoperiod have 
been contradictory [10,73]. Sharp et al. [10] observed an increase in LH during a 16-d 
treatment period with estradiol-17β in ovariectomized mares during vernal transition. 
Similarly, experiments conducted over the interovulatory period in the early (May and 
June) and late (August and September) breeding season have shown an increase in 
concentrations of LH following regression of the corpus luteum (CL) [72,74]. However, 
Mumford et al.[73] was unable to show any increase in LH over an 8-d treatment period 
or an increase in releasable LH following a GnRH agonist challenge. Similarly, estradiol 
for 4 d followed by GnRH + estradiol for an additional 4 d was unable to increase 
circulating concentrations of LH but, when challenged on day 10, an increase in 
releasable LH was observed [73]. At the cellular level, chronic treatment with estradiol 
has been shown to enhance LH biosynthesis in the vernal transitional mare [11]. In ovine 
pituitary cell cultures, estradiol increases the concentration of GnRH receptors but this 
has not been examined in the equine. Therefore, uncertainty remains regarding the 
influence of estradiol on the hypothalamic-pituitary axis of the mare and its potential 
interaction with GnRH during the anovulatory period.    
Objectives of the study reported here were to test the hypothesis that chronic 
treatment with estradiol, with or without simultaneous treatment with GnRH, will 
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increase circulating concentrations of LH and stimulate ovarian follicular growth in 
winter anovulatory mares during increasing photoperiod. 
                                                                                                                            
5.2 Materials and Methods 
 All animal-related experiments were approved by the Institutional Agricultural 
Animal Care and Use Committee (IAACUC) of the Texas A&M University System. 
 
5.2.1 Animals 
 Ten barren light horse mares, predominantly American Quarter Horses, were 
maintained on a pasture of mixed grasses and supplemented with Coastal Bermuda grass 
hay as needed to maintain a body condition score of 5 to 6 (1 to 9 scale) [79] at the 
Texas A&M AgriLife Research Station in Beeville, TX. 
 
5.2.2 Experimental procedures 
 Ovulatory status was monitored using transrectal ultrasonography (Honda HS-
Feb500V, Honda Electronics Co., LTD), starting the second week in January and 
continued for 4 wk prior to the start of the study. Mares were confirmed anovulatory 
based on the absence of a CL and no follicle > 30mm during this time period. Mares 
were stratified by largest follicle size and assigned randomly to one of 4 treatment 
groups: 1) Control [Sham pump and twice-daily i.m. injections of 2 mL corn oil; n = 5], 
2) GnRH [Alzet osmotic pump providing continuous subcutaneous delivery of GnRH 
(100 µg/h) and twice daily i.m. injections of 2 mL corn oil; n = 5], 3) Estradiol [sham 
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pump and twice daily i.m. injections of 5 mg estradiol in 2 mL corn oil; n = 5], 4) GnRH 
+ Estradiol [combination of treatments 2 and 3; n = 5]. The experiment was conducted 
during the non-breeding season and initiated in each treatment group over 2 consecutive 
days (February 12 and 13). An Alzet osmotic minipump (model 2ML2; DURECT Corp., 
Cupertino, CA) or sham pump constructed of Silastic tubing (Dow Corning Corporation, 
Midland, MI) filled with medical grade silicone adhesive (Dow Corning Corporation, 
Midland, MI) was implanted surgically under the skin on the first day of the experiment 
(day 0) and removed on day 14. Twice daily treatments with estradiol-17β or corn oil 
were begun on day 0 and continued until confirmation of ovulation or 14 d, whichever 
occurred first. Ovarian follicular populations were evaluated every 1 to 3 d using 
transrectal ultrasonography (Honda HS-Feb500V, Honda Electronics Co., LTD) 
beginning before pump insertion and ending on day 14 or following ovulation, 
whichever occurred first. Estrous behavior was determined daily in a large pen of 4 to 5 
mares using an intact stallion in an adjacent pen separated by a solid panel, with teasing 
scores assessed on a scale of 1 to 4 [53]. 
 
5.2.3 Subcutaneous pump insertion 
 The mare was placed in a stock and sedated with detomidine HCL 
(Dormosedan®, Florham Park, New Jersey, 20-40 µg/kg BW if required. An area at the 
base of the neck was clipped and prepared of aseptic surgery using an iodophore (Purdue 
Product LP, Stamford, CT), providone iodine solution (Prepodyne, WestArgo, Kansas 
City, MO), and 70% isopropanol. Three to five milliliters of a local anesthetic (lidocaine 
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HCl, 2%; Agri Laboratories, St. Joseph, Mo) was injected subcutaneously and a 2-cm 
incision was made through the skin with a sterile scalpel. A sterile, blunt instrument was 
used to expand the subcutaneous space, creating a pocket to accommodate the osmotic 
or sham pump. The incision was closed with #2 non-absorbable synthetic sutures 
(Supramid®) that was left in place for 7 d. The wound was dressed with a wound 
dressing for horses. On the last day of the experiment, the incision was re-opened and 
the pump was removed. The incision was closed again with #2 non-absorbable synthetic 
suture (Supramid®) and sutures were removed after 7 d.   
 
5.2.4 Blood sampling 
 Single blood samples were collected daily via jugular venipuncture starting 
immediately before pump insertion and placed into sterile 10-mL blood collection tubes 
containing 15.0 mg EDTA.  Samples were taken at approximately the same time every 
morning before the mares were treated and samples placed on ice or under refrigeration 
(4°C). Samples were centrifuged (562 x g) for 30 min at 4°C for the collection of 
plasma. Plasma samples were stored at -20°C until hormone analysis for concentrations 
of LH. 
 
5.2.5 Hormone analysis 
Plasma concentrations of LH were assayed in triplicate utilizing a double 
antibody RIA as validated previously in this laboratory [82]. A highly purified equine 
LH (LH AFP-5130A) was used for both iodinated tracer and standards. An anti-equine 
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LH antiserum (AFP-240580) was used at a dilution of 1:120,000. Highly-purified 
hormones and antisera were provided by Dr. A.F. Parlow, National Hormone and 
Peptide Program (NHPP), Harbor-UCLA Research and Education Institute, Los 
Angeles, CA. The sensitivity, intra- and interassay coefficients of variation were 0.25 
ng/mL, 11.1% and 10.3%, respectively for LH. 
 
5.2.6 Ultrasonography 
 Transrectal ultrasonography was performed every 1 to 3 d beginning prior to 
pump insertion. When a follicle ≥ 30 mm in diameter was detected, ultrasound 
examinations were performed daily until ovulation was confirmed. Upon conformation 
of ovulation, no further evaluations were performed. 
 
5.2.7 Estrous behavior 
 Mares were teased daily in a large pen of 5-6 mares using an intact stallion in an 
adjacent pen separated by a solid panel. Teasing scores were assessed utilizing a scale 
ranging from 1 to 4 (1, breaking down in the presence of the stallion; 2, winking in the 
presence of the stallion; 3, indifference to the stallion; 4, physical aggression evidenced 
by kicking, and ear-pinning) [53]. 
 
5.2.8 Statistical analysis 
 Analysis of repeated measures was used to determine main effects of treatment 
on temporal changes in serum hormone concentration and estrous behavior utilizing a 
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mixed model procedure of an add-in of JMP from the Statistical Analysis Systems (SAS; 
SAS Inst., Inc., Cary, NC)). The model included day or period as the within subject 
factor, treatment as the between-subject factor, and mare as the subject. Fixed effects 
were treatment, day or period, and treatment x day or treatment x period interaction. If 
fixed effects were found significant, a pair wise comparison was done using means 
Tukey’s HSD.  Main effects were considered significant when P ≤ 0.05 and a trend 
toward significance when P ≤ 0.10.   
 
5.3 Results 
5.3.1 Plasma LH 
Two mares from the GnRH treatment group ovulated on days 8 and 9, 
respectively and 1 mare from the GnRH + Estradiol (GnRH/E2) treatment group 
ovulated on day 9.  Therefore, the analysis of mean concentrations of LH among groups 
included values only up to the time of ovulation for those mares. Also, post-treatment 
concentrations of LH in mare 44 were 2 standard deviations above the mean of the 
treatment group. Therefore, mare 44 was removed from consideration (Fig. 5.1.).  
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Fig. 5.1. Individual concentrations of LH for mares in the estradiol-treated group. Mare 
44 exhibited an increase in circulating concentrations of LH, with a concentration 
(±SED) on day 14, 3.1 ± .1 ng/mL above the other 4 mares. 
 
Mean circulating concentrations of LH did not differ (P = 0.355) among 
treatment groups on day 0 (Fig. 5.2.). The main effects of treatment (P < 0.0001), and 
the treatment x day interaction (P < 0.0001) on peripherally circulating concentrations of 
LH were highly-significant. Post-treatment mean concentrations of LH were greater in 
mares treated with GnRH/E2 (P < 0.0002) and GnRH (P < 0.009) than in control mares. 
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Fig. 5.2. Least squares mean concentrations of LH over the 14-d treatment period, with 
all treatments beginning on day 0. Overall pooled mean concentrations of LH were 
greater for GnRH/E2 (P < 0.0002) and GnRH (P < 0.009) compared to the controls. 
Treatment x day interaction P < 0.0001.   
 
Because of the significant treatment x time interaction, a post-hoc analysis was 
performed in which concentrations of LH were pooled over 3-d periods to form 5 
periods (I - V).  Fig. 5.3 depicts pooled mean concentrations of LH over these 3-d 
periods. During Period I, concentrations of LH for both GnRH (P > 0.008) and 
GnRH/E2 (P < 0.001) were greater than the control.   During the second period, 
GnRH/E2 increased circulating LH concentrations above all other treatment groups (P < 
0.02) and continued to do so for the remaining periods. Concentrations of LH in the 
GnRH treatment group were also greater than the E2 and Control groups from the 
second period (P < 0.0001) through the remaining periods. During the second through 
the fifth periods, concentrations of LH in the GnRH/E2 group were also greater (P < 
0.02 to P < 0.004) than mares treated with GnRH only.  
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Fig. 5.3. Mean concentrations of LH pooled over 3-d periods within groups. Letters 
above bars (a,b and c,d) denote significant differences (P < 0.05) within periods. 
Estradiol treatments are denoted as E2 and GnRH/E2, respectively. Roman numeral I to 
V denote the five 3-d periods.    
 
5.3.2 Ovarian dynamics 
Three mares ovulated during the treatment period, 2 mares from the GnRH group 
(day 8 and 9) and 1 from the GnRH/E2 group (day 9). Mean maximum follicle size did 
not differ among treatment groups at the beginning of the experiment (P = 0.38; Fig. 
5.4A) or in response to any treatments, including those groups in which mares ovulated 
by day 14 (Fig. 5.4B).  However, mares receiving estradiol or estradiol + GnRH had 
numerically fewer follicles ≥ 30 mm than the GnRH group (Table. 5.1.) but a larger 
number of mares would be required to confirm statistically relevant effects.  
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Table 5.1.  Number of mares from each group that ovulated and the number of mares 
that had follicles > 30 mm. 
Treatment Ovulations Mares with follicle ≥ 30 mm 
Control 0 of 5 1 of 5 
Estradiol 0 of 5 0 of 5 
GnRH 2 of 5 3 of 5 
GnRH/E2 1 of 5 1 of 5 
 
 
Fig. 5.4. Mean size of the largest follicle on day 0 (A) and on day 14 or the day before 
ovulation in 2 GnRH and 1 GnRH/Estradiol mares that ovulated (B). Mean maximal 
follicle size did not differ among groups. 
 
5.3.3 Estrous behavior 
 Teasing scores for mares in the GnRH, Estradiol, and GnRH/E2 groups did not 
differ; however, all 3 of these groups had lower (P < 0.03) mean teasing scores in 
comparison to the control (Fig. 5.5.).  Mean teasing score within the Control group did 
decline (P < 0.01) over the 14-day period from a mean of 3.3 ± 0.5 on day 2 to 1.2 ± 0.4 
on day 14.  Mean duration of consecutive days of estrous behavior (teasing score of 1) 
were 8.4 ± 1.7 d, 6.8 ± 0.9 d, 6.4 ± 2.2 d, and 4 ± 0.5 d for Estradiol, GnRH, GnRH/E2, 
and Control and did not differ among groups. 
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Fig. 5.5. Least squares mean teasing scores beginning on day 2 and continuing through 
day 14 of the experiment. Mares were teased in small groups at the same time daily in a 
large pen adjacent to the stallion and separated by solid panels. Treatment x day (P < 
0.03) 
 
5.4 Discussion 
 Results of this study indicated that chronic treatment of winter anovulatory mares 
with estradiol alone had no effect on circulating concentrations of LH or follicular 
development. Although 1 mare exhibited a profound and sustained increase in 
circulating LH relative to other estradiol-treated mares, it is uncertain whether this was a 
reflection of individual responsiveness to the treatment or coincidental neuroendocrine 
transition. Because of the rapid increase in LH observed in this mare, it is tempting to 
speculate that individual mares may respond at different times to this treatment, 
depending upon endogenous secretion of basal GnRH or the ability of estradiol to trigger 
such an increase. In any case, such variation may explain some of the contradictions in 
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earlier reports [10,73] and may also indicate that both dose of estradiol and duration of 
treatment could contribute to variability observed.  
While estradiol alone did not increase circulating concentrations of LH, the 
current study demonstrated that treatment with estradiol enhanced responsiveness to 
chronic GnRH treatment designed to increase basal secretion of LH shown to stimulate 
growth of a preovulatory follicle. The ability of estradiol to increase pituitary 
responsiveness to GnRH has been shown previously in other species [85,94,95] and in 
some reports in the mare. In the latter case, chronic estradiol treatment failed to enhance 
the ability of a GnRH agonist to increase secretion of basal LH. This failure likely 
occurred in previous studies because of desensitization of GnRH receptors in response to 
continuous treatment with GnRH agonists which does not occur readily when native 
GnRH is employed [73]. Nonetheless, enhanced responsiveness to challenge with a 
bolus injection of GnRH was reported [73]. The effectiveness of continuous treatment 
with native GnRH alone to increase circulating concentrations of LH in anovulatory 
mares has been well documented and confirmed herein [53,82,89,96].  Although not 
examined in the mare, data from numerous other female mammals indicate that estradiol 
can up-regulate the GnRH receptor [85,97,98]. It is not possible to discern from the 
present study whether estradiol enhanced responsiveness to GnRH by increasing GnRH 
receptors or by direct hypothalamic effects or both. However, since estradiol alone did 
not appear to have significant effects on basal secretion of LH, we interpret our results to 
indicate that estradiol increased responsiveness to GnRH  by effects on pituitary 
receptors to GnRH or by increasing pituitary content of LH.  In an evaluation of 
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concentration and content of pituitary GnRH receptors, Hart et al. [18] observed no 
significant differences across reproductive seasons. Similarly, Silvia et al. [43] found no 
differences in concentration of GnRH receptors from the winter anovulatory period  to 
the breed season. However, there was a decrease in pituitary content of GnRH receptors 
during the anestrous period relative to the follicular phase of the estrous cycle. In the 
ewe, an increase in GnRH receptors in cultured pituitary cells has been shown following 
incubations with estradiol [85]. An increase in releasable LH may also stem from 
increased synthesis of LH occurring during increasing photoperiod and potential 
reproductive transition at the neuroendocrine level [11].  The latter infers increased basal 
secretion of GnRH that is required to stimulate synthesis of gonadotropin.  
While concentrations of LH differed among treatment groups, mean follicular 
size did not differ over the the14-d experimental period (Fig. 5.4.). Although the current 
work was not designed to provide sustained stimulation past 14 d, increases in LH in 
response to continuous treatment with native GnRH requires approximately 3 wk in 
order to effect the development of a preovulatory follicle in 85% of treated mares 
[53,89]. Ovulations did occur in both the GnRH and the GnRH/E2 group during the trial 
but, due to individual mare variation, 14 d was not adequate to make significant 
conclusions regarding ovarian effects of combining estradiol with GnRH treatments. 
One caveat to this approach is that estradiol has been shown to suppress FSH 
concentrations in several female mammals [99-101], including the mare [73]. Thus, it is 
possible for estradiol to suppress follicle growth while at the same time enhancing 
secretion of LH. This needs to be evaluated in further experiments since recruitment of 
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antral follicles for final maturation in response to LH for any of these treatments to be 
effective.    
Within a few days following the initiation of treatments, the majority of the 
mares from the Estradiol, GnRH/E2 and GnRH groups expressed a teasing score of 1. 
Behavior scores were somewhat variable in each of the three groups with some of the 
mares maintaining a teasing score of 1 for the entirety of the study, while others 
expressed estrous behavior more infrequently. In estradiol-treated groups, such a 
response was to be expected given the high pharmacological dose and stimulatory 
effects of exogenous estradiol on the CNS [102]. The expression of estrus in mares 
treated only with GnRH (GnRH group) was likely due to steroidogenic activity in small 
follicles similar to that seen by Thorson et al. [75] and others following native GnRH 
treatment [51,52,80]. One report suggested that this may be related to stimulation of 
angiogenic factors associated with follicular growth [71].  However, by the end of the 
trial, mean teasing scores for mares in the control group did not differ from that of the 
other treatment groups. This can partially be explained by two of the mares in the control 
group that had begun to develop large follicles near the end of the study.  For mares with 
only small follicles, such teasing behavior is much less explainable but is commonly 
reported [103] . It may occur as a result of biostimulation when exposed to a stallion, the 
approach of vernal transition and increased steroidogenic activity of small follicles, or 
other social factors that are not well-characterized.  
In conclusion, the current study indicates that estradiol plays a role in modulating 
pituitary responsiveness to GnRH in the mare. In the current work, this occurred during 
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increasing photoperiod.  However, it is likely that the same response would have 
occurred at other times in the presence of significant GnRH stimulation.  Although not 
the main focus of the study, ovarian data hinted that estradiol treatment at a 
pharmacological dose may not provide advantages to the advancement of ovarian 
recrudescence. Additional work is required in order to clarify this issue. Such 
investigations could provide a better understanding of the underlying mechanisms 
mediating the transition from anovulatory to ovulatory status and the development of 
additional approaches for hastening reproductive transition. 
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CHAPTER VI 
CONCLUSION 
 
The results of studies reported herein have expanded upon RF9’s action in the 
mare relative to previously-published data. Experiments confirmed that RF9 increases 
secretion of LH in the winter anovulatory mare and that estradiol pretreatment enhances 
responsiveness to RF9. In addition, we demonstrated that the effect of RF9 on secretion 
of FSH is similar to its effects on LH.  Clearance rate studies revealed that the terminal 
half-life of RF9 in the circulatory system of the mare is approximately 40 min. Thus, its 
value as a pharmacological agent may be limited to its ability to cause an acute response 
unless practical and economical methodologies for prolonging its action are developed. 
Finally, we demonstrated in vivo that estradiol enhances anterior pituitary 
responsiveness to GnRH in the winter anovulatory mare. This effect was realized when 
estradiol was injected daily in conjunction with chronic, subcutaneous infusion of 
GnRH. The latter treatment approach has been demonstrated previously to rapidly 
accelerate the timing of the first annual ovulation in 85% of seasonal anovulatory mares 
[8]. However, other issues related to effects of estradiol on secretion of FSH and ovarian 
follicular development must be examined in greater depth before a role for estradiol in 
this setting can be confirmed.  
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APPENDIX 
 
Methodology 
Equine LH radioimmunoassay 
1. Iodinated Product: Iodination grade eLH (AFP-5130A) 
2. Antibody: Anti-equine LH (AFP-240580). Dilution 1:100,000 
3. Standards (stds): Iodination grade equine LH (AFP-5130A; 0.1 – 20.0 ng/mL) 
4. References (ref): equine LH added to equine serum 
5. RIA Procedure: 
A. Day 1: Begin Assay 
1. NSB – 500 μL of 1% PBS-EW (egg white) 
2. Std – 500 μL of 1% PBS-EW 
3. Stds – 200 μL std + 300 μL of 1% PBS-EW 
4. Ref – 200 μL ref + 300 μL of 1% PBS-EW 
5. Unknown – 200 μL unknown sample + 300 μL of 1% PBS-EW 
6. Pipette 200 μL of PBS-EDTA + 1:400 NRS without primary antibody            
into NSB tubes only 
7. Pipette 200 μL of anti-eLH (diluted in PBS-EDTA + 1:400 NRS) into all 
tubes except NSB and TC tubes 
8. Pipette 100 μL 125I-eLH (20,000 cpm/100 μL diluted in 1% PBS-EW) 
into all tubes 
9. Vortex tubes briefly and incubate for 24 h at 4°C 
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B. Day 2: Add Second Antibody 
1. Pipette 200 μL of Sheep-anti-rabbit gamma globulin (SARGG; 2nd Ab) 
diluted in PBS-EDTA without NRS into all tubes except TC tubes 
2. Vortex tubes briefly and incubate for 48-72 h at 4°C 
C. Day 4: Pour Off Assay 
1. Add 3 mL ice cold PBS (0.01 M; pH 7.0) to all test tubes except TC tubes 
2. Centrifuge tubes for 1 h at 4°C at 3600 rpm 
3. Decant supernatant 
4. Count radioactivity of each tube using a gamma counter 
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Equine FSH Radioimmunoassay 
 
1. Iodinated Product: Iodination grade eFSH (AFP-5022B) 
2. Antibody: Anti-equine FSH (AFP-2062096). Dilution 1:12,500 
3. Standards (stds): Iodination grade eFSH (AFP-5022B; 0.5 – 25 ng/mL) 
4. References (ref): eFSH added to equine plasma 
5. RIA procedure: 
A. Day 1: Begin Assay 
1. NSB - 500 µL of 1% PBS-EW (egg white). 
2. 0 Std - 500 µL of 1% PBS-EW. 
3. Stds - 200 µL std + 300 µL of 1% PBS-EW. 
4. Ref - 200 µL ref + 300 µL of 1% PBS-EW. 
5. Unknown - 200 µL sample + 300 µL of 1% PBS-EW. 
6. Pipette 200 µL of PBS-EDTA + 1:400 NRS without primary antibody 
into NSB tubes only. 
7. Pipette 200 µL of anti-eFSH (diluted in PBS-EDTA + 1:400 NRS) into 
all tubes except NSB and TC tubes. 
8. Vortex tubes briefly and incubate for 1 h at room temperature. 
9. Pipette 100 µl 125I-eFSH (20,000cpm/100 µl diluted in 0.1% PBS-EW) 
to all tubes. 
10. Vortex tubes briefly and incubate for 24 h at 4°C. 
B. Day 2: Add Second Antibody 
1. Keep all test tubes and reagents on ice during all procedures. 
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2. Pipette 200 µl of Sheep-anti-rabbit gamma globulin (SARGG; 2nd Ab) 
diluted in PBS-EDTA without NRS into all tubes except TC tubes. 
3. 3. Vortex tubes briefly and place in refrigerator for 48-72 h at 4°C. 
C. Day 4: Take Off Assay 
1. Keep all test tubes and reagents on ice during all procedures. 
2. Add 3.0 mL ice cold PBS (0.01 M; pH 7.0) to all tubes except TC tubes. 
3. Centrifuge tubes for 1 h at 4°C at 3600 rpm. 
4. Decant supernatant. 
5. Count radioactivity of each tube using a gamma counter.  
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Extraction and LC/MS protocol for curve 
Tube #1 #2 #3 #4 #5 #6 #7 #8 
[RF9] 2ng/
mL 
5ng/
mL 
10ng/
mL 
20ng/
mL 
50ng/
mL 
100ng/
mL 
300ng/
mL 
500ng/
mL 
PBS 98ul 95ul 90ul 80ul 50ul 0ul 85ul 75ul 
D1 2ul 5ul 10ul 20ul 50ul 100ul ----------
---- 
-----------
--- 
WS --------
--- 
--------
--- 
--------
----- 
----------
--- 
----------
--- 
---------
----- 
15ul 25ul 
Plasma 100ul 100ul 100ul 100ul 100ul 100ul 100ul 100ul 
 
Reagents 
A. Stock = 2ug/mL RF9 in PBS 
B. Working Stock = 100ng/mL RF9 
C. Extraction solvent = Acetonitrile w/ 0.1% Formic Acid 
D. Resuspension Solvent = mEQ water w/ 10% acetonitrile and 0.1% Formic Acid 
@100ng/mL testosterone-D3 
 
Procedures 
1. Pipette PBS to labeled Eppendorf tubes (see above table) 
2. Pipette RF9 (see above table) 
3. Pipette 100 µL of plasma  
4. Vortex briefly, allow few minutes to equilibrate 
5. Pipette 500 µL, acetonitrile-0.1% formic acid (standard and unknowns treated the 
same from this point on)   
6. Vortex for 30 sec. and let set for 2 min to equilibrate  
7. Centrifuge 15min @ 13K rpm 
8. Extract 400ul supernatant, take care not to disturbing pellet  
9. Spin Vac w/ heat for 1h 20 min. 
10. Pipette 100ul mEQ water-10%acetonitriloe-0.1% formic acid + testosterone-D3 
11. Vortex a minimum of 30 sec.  
12. Sonicate in water bath for 10 min. 
13. Centrifuge 5 min. @13K rpm 
14. Extract 40ul for single injection or 80ul for duplicates and pipette into disposable 
glass nipple          tube, insert nipple tube into reusable glass vial and screw 
penetrable cap down tight 
